OBJECTIVE: The potential benefit of adjuvant hepatic arterial infusion remains unknown for @entity1 with @entity14 after radical hepatic resection. The principle aim of this study was to investigate the long-term outcome of adjuvant hepatic arterial infusion. METHODS: Eligible trials were identified from Embase, PubMed, the Web of Science, and the Cochrane library since their inception to June 1, 2014. @entity1 with @entity14 , who underwent radical hepatic resection and received adjuvant hepatic arterial infusion, were enrolled. The study outcomes included 5-year disease-free and overall survival rate, respectively. Hazard ratio with a 95  % confidence interval was used to measure the pooled effect according to a random effects model or fixed effects model, depending on the heterogeneity between the included studies. The statistical heterogeneity between trials was detected by I (2) test. Sensitivity analyses were also carried out. RESULTS: A total of nine studies containing 1057 @entity1 were included. The comparison indicated that the overall pooled hazard ratio for 5-year overall survival was 0.75 (95  % CI: 0.56-0.99, p   =   0.048). The hazard ratio for 5-year disease-free survival rate was 0.61 (95  % CI: 0.48-0.79, p   =   0.001). When compared with systemic chemotherapy alone, adjuvant hepatic arterial infusion plus systemic chemotherapy also improved the long-term survival. CONCLUSIONS: Adjuvant hepatic arterial infusion improved the 5-year disease-free and overall survival rate, respectively. It should be recommended for @entity1 with a high risk of recurrence, but these findings require prospective confirmation.

A systematic review and meta-analysis to reappraise the role of adjuvant hepatic arterial infusion for XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'Patients'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal liver metastases']
@entity14 :: (MESH:D015179,Disease) :: ['colorectal cancer liver metastases']
